Several Billion Dollars in Free Government support is going to Critical Mineral Companies and the Market has completely overlooked the impact it will have on specific stocks!
Category: News
This Apparel Powerhouse is Looking Stylish, Here’s Why…
With remarkable growth and strategic partnerships, this company could be one of the most promising brands to emerge in the apparel and wellness markets…
Is This Company The Solution To World Hunger?
As one of only three North American companies who specialize in cellular agriculture, this company is perfectly positioned to solve world hunger and meet today’s demand with tomorrow’s supply. This presents insane growth potential.
Why Are Analysts Amped Up For This Battery Company?
Revolutionizing Energy Storage: Could This Battery Game-Changer Be Poised For A 1,000% Move Back To Its 52-Week High After Recently Bouncing Off Its 52-Week Low?
This AI Stock Is Ready For Takeoff
NASDAQ: BCAN | CSE: BYND This Little-Known “AI Stock” Has an Extremely Low Float And is Poised to Disrupt a Lucrative $62 Billion Market After Recent Patent News… See why now could be the best time to start your research on BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) (CSE:BYND). Chart Website Price Targets $1.79 +15% $1.95 +25%… Continue reading This AI Stock Is Ready For Takeoff
Parkinson’s Treatment FDA Approval Solidifies Massive Upside Potential
After the FDA delivered an approval to this low float biotech, its already mammoth potential grew even bigger. In line with the primed nano-cap market, see why this company is a potential goldmine.
Orphan Drug Designation and New Patent Means Immense Potential For This Micro-Float
This Orphan Drug Designated micro-float was just granted it’s 8th Patent after bouncing off it’s 52-week low, prompting a Wall St. Analyst to assign a +500% price target.
Senior Zack’s Analyst Provides 1,832 Percent Target On This Small Cap Tech Stock
After partnering with AT&T and Verizon and receiving a Zack’s Analyst Valuation target 1,832% above market price, this nano-cap tech stock could experience a huge growth period. Now is the time to watch it like a hawk!
Senior Life Sciences Analyst From Noble Financial Says This Gene Therapy Stock Could Climb Over 400%
Robert LeBoyer, a Senior Life Sciences Analyst at Noble Financial doubled down on his Outperform rating with a 400% upside after this company signed an exclusive University license agreement.
This Prime Opportunity to Hedge Against The Looming Recession Is On Your Screen Right Now
With a market recession looming overhead and an increasing surge of online commerce, this pawn service connection app is filling a huge technical gap for millions, and our portfolios
